These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 2331850)

  • 21. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
    Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM
    J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
    Wasilauskas BL
    Diagn Microbiol Infect Dis; 1989; 12(1):39-43. PubMed ID: 2714071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
    Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
    J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.
    Betriu C; Cabronero C; Gomez M; Picazo JJ
    Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):352-6. PubMed ID: 1396757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermenters.
    Fass RJ; Gregory WW; D'Amato RF; Matsen JM; Wright DN; Young LS
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2256-9. PubMed ID: 2073118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility of anaerobic bacteria to beta-lactam antibiotics in the United States.
    Johnson CC
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S371-6. PubMed ID: 8324150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial susceptibility of anaerobic bacteria in Australia.
    Chen SC; Gottlieb T; Palmer JM; Morris G; Gilbert GL
    J Antimicrob Chemother; 1992 Dec; 30(6):811-20. PubMed ID: 1289355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.
    Jones RN; Wilson HW; Thornsberry C; Barry AL
    Diagn Microbiol Infect Dis; 1985 Nov; 3(6):489-99. PubMed ID: 2998694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan.
    Watanabe K; Ueno K; Kato N; Muto Y; Bandoh K; Tanaka Y; Jotwani R; Goto M; Shimada K; Shimizu K
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1069-73. PubMed ID: 1295761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.
    Cuchural GJ; Snydman DR; McDermott L; Iannini PB; Hill GB; Cleary TJ; O'Keefe JP; Pierson CL; Rihs JD; Finegold SM
    Clin Ther; 1992; 14(1):122-36. PubMed ID: 1576621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of cefoperazone-sulbactam combination against gram negative bacilli.
    Poudyal N; Gyawali N; Gurung R; Bhattarai NR; Baral R; Khanal B; Shrestha S; Amatya R; Bhattacharya SK
    Nepal Med Coll J; 2012 Mar; 14(1):5-8. PubMed ID: 23441486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.
    Barry AL; Jones RN
    J Clin Microbiol; 1988 Jan; 26(1):13-7. PubMed ID: 3343304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in vitro activity of cefoperazone and various combinations of cefoperazone/sulbactam.
    Knapp CC; Sierra-Madero J; Washington JA
    Diagn Microbiol Infect Dis; 1990; 13(1):45-9. PubMed ID: 2331849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of cefoperazone-sulbactam combinations against cefoperazone-resistant clinical bacterial isolates.
    Eliopoulos GM; Klimm K; Ferraro MJ; Moellering RC
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):624-6. PubMed ID: 2506024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.
    Jones RN; Barry AL; Packer RR; Gregory WW; Thornsberry C
    J Clin Microbiol; 1987 Sep; 25(9):1725-9. PubMed ID: 3498740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of minocycline alone and in combination with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii.
    Pei G; Mao Y; Sun Y
    Microb Drug Resist; 2012 Dec; 18(6):574-7. PubMed ID: 22928863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study.
    Bandoh K; Ueno K; Watanabe K; Kato N
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S382-6. PubMed ID: 8324152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.
    Barry AL; Jones RN; Packer RR
    J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222
    [No Abstract]   [Full Text] [Related]  

  • 40. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
    Nord CE; Olsson-Liljequist B
    Scand J Infect Dis Suppl; 1984; 43():44-9. PubMed ID: 6100139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.